CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Eli Lilly and Company v. Sun Pharmaceutical Industries, Ltd.

2:16-cv-00518

Overview

Case Number 2:16-cv-00518
Filing Date 2016-09-02
Status Terminated
Termination Date 2016-09-15
Court District Court, E.D. Virginia (vaed)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Sun Pharmaceutical Industries, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Sun Pharmaceutical Industries, Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Sun Pharma Global FZE Operating Company

Represented By

0 Attorneys Listed
No attorneys available

ICOS Corporation NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Laura P. Masurovsky

Finnegan Henderson Farabow Garrett & Dunner LLP

Tel: +1 (202) 408-4000

901 New York Ave NW, Washington, DC 20001-4413

Charles E. Lipsey

Finnegan Henderson Farabow Garrett & Dunner LLP (VA)

Tel: +1 (571) 203-2700
Fax: +1 (202) 408-4400

11955 Freedom Dr, Suite 800

Eli Lilly and Company Operating Company

Represented By

2 Attorneys Listed

Laura P. Masurovsky

Finnegan Henderson Farabow Garrett & Dunner LLP

Tel: +1 (202) 408-4000

901 New York Ave NW, Washington, DC 20001-4413

Charles E. Lipsey

Finnegan Henderson Farabow Garrett & Dunner LLP (VA)

Tel: +1 (571) 203-2700
Fax: +1 (202) 408-4400

11955 Freedom Dr, Suite 800

Court & Judges

Court

District Court, E.D. Virginia (vaed)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials 6 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 6 U.S. Courts: 3
USPTO PTAB Trial 2018-06-07
IPR2018-01183

Aquestive Therapeutics, Inc. v. ICOS Corporation et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2017-07-12
IPR2017-01762

Argentum Pharmaceuticals LLC v. ICOS Corporation

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2017-07-10
IPR2017-01757

Dr. Reddy's Laboratories, Inc. v. ICOS Corporation

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-12-06
IPR2017-00412

MonoSol Rx, LLC v. ICOS Corporation et al.

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2016-11-22
IPR2017-00323

Mylan Pharmaceuticals Inc. v. ICOS Corporation

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2016-02-26
IPR2016-00678

IntelGenx Corp. v. ICOS Corporation et al.

Asserted Patent
Status: Institution Denied
U.S. District Court 2016-11-30
1:17-cv-00015

Eli Lilly and Company v. Apotex, Inc.

Asserted Patent
Status: VAED
U.S. District Court 2016-09-02
2:16-cv-00519

Eli Lilly and Company v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: VAED
U.S. District Court 2016-09-02
1:16-cv-01169

Eli Lilly and Company v. Teva Pharmaceuticals USA Inc.

Asserted Patent
Status: VAED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6943166
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
Filed: 2000-04-26
Issued: 2005-09-13
Expired (Term Ended)
Expires: 2020-04-26

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(6 total)
Pleading / Complaint

COMPLAINT against Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd. ( Filing fee $ 400, receipt number 14683061283.), filed by ICOS Corporation, Eli Lilly and Company. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet, # 3 Letter, # 4 Receipt)(epri) (Entered: 09/09/2016)

Entry #1 • 2016-09-02
1

Financial Interest Disclosure Statement (Local Rule 7.1) by Eli Lilly and Company, ICOS Corporation. (epri) (Entered: 09/09/2016)

Entry #2 • 2016-09-02
1

Report on the filing or determination of an action regarding patent 6,943,166. (epri) (Entered: 09/09/2016)

Entry #3 • 2016-09-09
1

Three Summonses, each with service copy, Issued as to Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd. (Attachments: # 1 Civil Motions Procedures)(epri) (Entered: 09/09/2016)

Entry #4 • 2016-09-09
1

Three Summonses, each with service copy, Issued as to Sun Pharma Global FZE, Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd. (Attachments: # 1 Civil Motions Procedures)(epri) (Entered: 09/09/2016)

Entry #4 • 2016-09-09
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc